Navigation Links
Risk of Hemorrhage Increased in Vaginally Born Babies

A first study, appearing in the February issue of Radiology, to use Magnetic Resonance Imaging (MRI) to study the brains of a large group of babies// soon after birth found a small amount of bleeding in and around the brains of one in four babies who were delivered vaginally.

"Small bleeds in and around the brain are very common in infants who are born vaginally," said John H. Gilmore, M.D., professor of psychiatry and Vice-Chair for Research and Scientific Affairs at the University of North Carolina School of Medicine in Chapel Hill. "It seems that a normal vaginal birth can cause these small bleeds."

For the study, 88 asymptomatic infants, equally divided between male and female, underwent MRI between the ages of one and five weeks. Sixty-five had been delivered vaginally and 23 had been delivered by cesarean section.

MR images showed that 17 (26 percent) of the babies who had been delivered vaginally had intracranial hemorrhages (ICH), or small bleeds in and around the brain. Seven infants had two or more types of ICH. Prior studies have shown a smaller incidence—approximately 10 percent—of intracranial hemorrhage associated with vaginal birth.

While ICH was significantly associated with vaginal birth, it was not dependent on prolonged duration of labor or on traumatic or assisted vaginal birth.

"In our study, neither the size of the baby or the baby's head, the length of the labor, nor the use of vacuum or forceps to assist the delivery caused the bleeds," Dr. Gilmore said. "The bleeds are probably caused by pressure on the skull during delivery."

In a newborn, the bones of the skull have not fused together, so the bones of the skull can shift and frequently overlap each other during vaginal delivery, to allow the baby's head to fit through the birth canal. This shifting can compress the brain or cause blood vessels to tear, which causes bleeding.

Most of the bleeds identified w
'"/>




Page: 1 2

Related medicine news :

1. Clazosentan May help to Improve Blood Circulation after Brain Hemorrhage due to burst Aneurysm
2. Aspirin reduces Hemorrhage recurrence
3. Retinal Hemorrhage: No More a Sure Sign of Child Abuse
4. Diagnosing Subarachnoid Hemorrhage
5. Risk of Brain Hemorrhage Rises with Old Age
6. Drug Linked to Increase in Brain Hemorrhage Cases
7. Use of Cellular Phones associated with Increased risk of Brain Tumors
8. Increased Heart Attack Risk From Celebrex,Vioxx
9. Allergy Risk Increased by Kerosene Use
10. Fewer teeth & Increased Ischemic Stroke risk
11. Young Smokers at Increased Risk Of Developing a Heart Attack
Post Your Comments:
Breaking Medicine News(10 mins):Health News:Kaiser Permanente Gives $5 Million to Children's Healthcare of Atlanta 2Health News:Kaiser Permanente Gives $5 Million to Children's Healthcare of Atlanta 3Health News:Blues CEO Encourages Graduates to Stay and Lead Michigan 2Health News:Bears Quarterback Jay Cutler and Eli Lilly and Company Will Send 44 Kids to American Diabetes Association Camps Through the Touchdowns for Diabetes Campaign 2Health News:Bears Quarterback Jay Cutler and Eli Lilly and Company Will Send 44 Kids to American Diabetes Association Camps Through the Touchdowns for Diabetes Campaign 3Health News:Bears Quarterback Jay Cutler and Eli Lilly and Company Will Send 44 Kids to American Diabetes Association Camps Through the Touchdowns for Diabetes Campaign 4Health News:Blood stem-cell transplant regimen reverses sickle cell disease in adults 2Health News:Blood stem-cell transplant regimen reverses sickle cell disease in adults 3Health News:Blood stem-cell transplant regimen reverses sickle cell disease in adults 4Health News:NICE guidelines ration affordable osteoporosis drugs 2Health News:NICE guidelines ration affordable osteoporosis drugs 3
Breaking Medicine Technology:The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8The First SamarionSolution Installed in Lake Charles Alzheimers Facility 53237 1The First SamarionSolution Installed in Lake Charles Alzheimers Facility 53237 2Blue Cross and Blue Shield of Texas Collaborates With Five Blue Plans to Increase Transparency Expand Access to Health Care Cost Information 53234 1Blue Cross and Blue Shield of Texas Collaborates With Five Blue Plans to Increase Transparency Expand Access to Health Care Cost Information 53234 2Montefiore Medical Center and Albert Einstein College of Medicine Herald New Agreement To Continue Forty Plus Year Historic Relationship 4796 1Montefiore Medical Center and Albert Einstein College of Medicine Herald New Agreement To Continue Forty Plus Year Historic Relationship 4796 2Montefiore Medical Center and Albert Einstein College of Medicine Herald New Agreement To Continue Forty Plus Year Historic Relationship 4796 3Montefiore Medical Center and Albert Einstein College of Medicine Herald New Agreement To Continue Forty Plus Year Historic Relationship 4796 4
Other Medicine Technology:Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 2Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 3Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 4Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 5Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 6Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 7New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 2New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 3New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 4New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 5New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 6New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 7New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 8